Page last updated: 2024-11-13

rome

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Rome: The capital city of Italy. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

(2R)-2-amino-2-(methoxymethyl)-4-(4-octylphenyl)butan-1-ol : A 2-amino-2-(methoxymethyl)-4-(4-octylphenyl)butan-1-ol that has R-configuration. It is a sphingosine kinase-2 inhibitor. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID71458556
CHEMBL ID2158686
CHEBI ID167668
MeSH IDM0019257

Synonyms (12)

Synonym
(r)-fty720 methyl ether
CHEBI:167668
(2r)-2-amino-2-(methoxymethyl)-4-(4-octylphenyl)butan-1-ol
(r)-fty720-ome
CHEMBL2158686 ,
bdbm50393641
gtpl6625
rome
1382486-90-9
Q27088607
benzenebutanol, beta-amino-beta-(methoxymethyl)-4-octyl-, (betar)-
benzenebutanol, -amino--(methoxymethyl)-4-octyl-, (r)-

Research Excerpts

Effects

The Rome IV criteria have been established as an international standard for diagnosing disorders of gut-brain interaction. The Rome criterion has shown its high reliability in detecting persistence.

ExcerptReferenceRelevance
"Rome has a population of approximately 2,800,000, with 6100 census tracts (CTs). "( Inequality in health: socioeconomic differentials in mortality in Rome, 1990-95.
Ancona, C; Dell'Orco, V; Forastiere, F; Fusco, D; Michelozzi, P; Perucci, CA, 1999
)
1.98
"The Rome criterion has shown its high reliability in detecting persistence."( Interpretation of intraoperative parathyroid hormone monitoring according to the Rome criterion in primary hyperparathyroidism.
Antonini, R; Calagna, S; Cipolla, C; Cocorullo, G; Contino, S; Corigliano, A; Graceffa, G; Mazzola, S; Melfa, G; Orlando, G; Proclamà, MP; Scerrino, G, 2022
)
1.43
"The Rome IV criteria have been established as an international standard for diagnosing disorders of gut-brain interaction. "( Upper gastrointestinal endoscopic findings in functional constipation and irritable bowel syndrome diagnosed using the Rome IV criteria: a cross-sectional survey during a medical check-up in Japan.
Fujiwara, Y; Fukumoto, S; Fukunaga, S; Hosomi, S; Kamata, N; Kimura, T; Nadatani, Y; Nagami, Y; Ominami, M; Otani, K; Taira, K; Takahashi, K; Tanaka, F; Watanabe, T, 2023
)
1.69

Toxicity

ExcerptReferenceRelevance
"In medicine, an adverse effect (AE) is a harmful and undesired effect resulting from a medication or intervention and procedures."( Adverse effects.
Rossini, PM, 2010
)
0.36
"Pegylated-interferon (peg-IFN) and ribavirin combination therapy for the treatment of hepatitis C virus (HCV) infection is well known to be associated with significant adverse effects."( Distortion-product otoacoustic emissions: a useful test for monitoring ototoxicity induced by pegylated interferon and ribavirin treatment in patients with chronic hepatitis C.
Casale, M; Faiella, F; Galati, G; Mazzarelli, C; Pappacena, M; Picardi, A; Potena, M; Salvinelli, F; Vespasiani Gentilucci, U,
)
0.13
" Our findings support the suggestion that reprocessing after storage can be avoided in the safe usage of the instrument if earlier decontaminations are performed correctly."( Is reprocessing after disuse a safety procedure for bronchoscopy?: A cross-sectional study in a teaching hospital in Rome.
Bruno, S; Ficarra, MG; Grieco, G; Laurenti, P; Marino, M; Moscato, U; Orecchio, F; Ricciardi, W; Turnaturi, C, 2012
)
0.59
"The chimney graft (CG) technique, based on the deployment of a covered stent parallel to the aortic endograft, has been proposed to achieve a safe proximal fixation extending the sealing zone."( Is the chimney graft technique a safe and feasible approach to treat urgent aneurysm and pseudoaneurysm of the abdominal aorta? An analysis of our experience and technical considerations.
Accrocca, F; Gabrielli, R; Marcucci, G; Siani, A, 2013
)
0.39
" At least one side effect was reported by 19."( Treating lupus patients with antimalarials: analysis of safety profile in a single-center cohort.
Alessandri, C; Ceccarelli, F; Conti, F; Garufi, C; Massaro, L; Miranda, F; Morello, F; Moscarelli, E; Perricone, C; Spinelli, FR; Truglia, S; Valesini, G, 2018
)
0.48
" The absence of contamination in all tested samples confirms the suitability of adopted procedures to ensure a safe product, considering the increased vulnerability of newborns, especially if preterm."( [Hygienic safety of infant milk powder formulas in hospital setting].
Berloco, F; Cambieri, A; Laurenti, P; Posteraro, B; Quaranta, G; Turnaturi, C; Vincenti, S,
)
0.13
" Subjective perception of a safe diet was high: 64·2 % of respondents believed they have a balanced diet."( Factors affecting safe and healthy diet in older adults in Italy: results of a preliminary study performed in a community-dwelling sample.
Barbara, A; Bernabei, R; De Meo, C; de Waure, C; Landi, F; Laurenti, P; Manes-Gravina, E; Moro, D; Ricciardi, W; Sacchini, D; Sgadari, A; Spagnolo, AG; Varacca, A, 2020
)
0.56
" Specific and targeted educational interventions for the elderly and their caregivers could improve the adoption of recommended food safety practices and safe nutritional behaviours among older adults."( Factors affecting safe and healthy diet in older adults in Italy: results of a preliminary study performed in a community-dwelling sample.
Barbara, A; Bernabei, R; De Meo, C; de Waure, C; Landi, F; Laurenti, P; Manes-Gravina, E; Moro, D; Ricciardi, W; Sacchini, D; Sgadari, A; Spagnolo, AG; Varacca, A, 2020
)
0.56
" Gemelli" University hospital new protocols were adopted for the safe management of patients affected by SARS-CoV-2."( COVID-19 pandemic: management of patients affected by SARS-CoV-2 in Rome COVID Hospital 2 Trauma Centre and safety of our surgical team.
De Mauro, D; Falez, F; Liuzza, F; Maccauro, G; Meschini, C; Mocini, F; Rovere, G; Smimmo, A; Ziranu, A, 2020
)
0.79
" Conversely, trans-thoracic (trans apical and trans-aortic) routes are the least safe and should be reserved only to sporadic cases."( All roads lead to Rome, but some are safer.
Calafiore, AM; Di Mauro, M; Lorusso, R, 2021
)
0.96
" Lastly, the adverse effects of probiotics were evaluated."( Efficacy and safety of probiotics in the treatment of irritable bowel syndrome: A systematic review and meta-analysis of randomised clinical trials using ROME IV criteria.
Chourdakis, M; Efstathiou, S; Germanidis, G; Kitsikidou, E; Konstantis, G; Pourzitaki, C, 2023
)
1.14

Compound-Compound Interactions

ExcerptReferenceRelevance
"The anthracycline analogue idarubicin, either alone or in combination with other antineoplastic drugs, has shown antileukemic activity in relapsed and refractory acute lymphoblastic leukemia (ALL)."( A single high dose of idarubicin combined with high-dose ABA-C (MSKCC ALL-3 protocol) in adult and pediatric patients with acute lymphoblastic leukemia. Experience at the University La Sapienza of Rome.
Annino, L; Arcese, W; Chiaretti, S; D'Elia, G; Del Giudice, I; Ferrari, A; Giona, F; Mandelli, F; Moleti, ML; Testi, AM; Todisco, E,
)
0.32
"The anthracycline analogue idarubicin, either alone or in combination with other antineoplastic drugs, has shown antileukemic activity in relapsed and refractory acute lymphoblastic leukemia (ALL)."( A single high dose of idarubicin combined with high-dose ARA-C (MSKCC ALL-3 protocol) in adult and pediatric patients with acute lymphoblastic leukemia. Experience at the University "La Sapienza" of Rome.
Annino, L; Arcese, W; Chiaretti, S; D'Elia, G; Del Giudice, I; Ferrari, A; Giona, F; Mandelli, F; Moleti, ML; Testi, AM; Todisco, E,
)
0.32
" Among these, an innovative viscosupplement has been produced from high a concentration of HA combined with a high concentration of sorbitol as a free radical scavenger."( Duration of symptom relief after intra-articular injection of hyaluronic acid combined with sorbitol (anti-ox-vs) in symptomatic hip osteoarthritis.
Bizzi, E; Cassol, M; Granata, M; Massafra, U; Migliore, A; Tormenta, S,
)
0.13

Bioavailability

ExcerptReferenceRelevance
" The results obtained in the field with the rapid test were compared with those obtained in the laboratory following the conventional procedure commonly used to evaluate metal bioavailability (diethylenetriaminepentaacetic extraction)."( A field screening test for the assessment of concentrations and mobility of potentially toxic elements in soils: a case study on urban soils from Rome and Novi Sad.
Angelone, M; Armiento, G; Čabilovski, R; Cremisini, C; Crovato, C; Manojlović, M; Montereali, MR; Pinto, V; Schiavella, F, 2017
)
0.66
"In a cross-sectional study we analysed endothelial function, as assessed by flow-mediated dilation (FMD), and oxidative stress, as assessed by Nox2 activation, serum isoprostanes and nitric oxide bioavailability (NOx), in patients with NASH (n = 19), FLD (n = 19) and controls (n = 19)."( Effects of dark chocolate on endothelial function in patients with non-alcoholic steatohepatitis.
Angelico, F; Baratta, F; Battaglia, S; Carnevale, R; Ceci, F; Del Ben, M; Loffredo, L; Ludovica, P; Nocella, C; Novo, M; Pannitteri, G; Violi, F, 2017
)
0.46

Dosage Studied

ExcerptRelevanceReference
"This study shows a dose-response effect between personal exposure to benzene and urinary 8-OHdG concentration; further studies are needed to clarify the biological significance of 8-OHdG as a marker of cancer risk."( Exposure to benzene and urinary concentrations of 8-hydroxydeoxyguanosine, a biological marker of oxidative damage to DNA.
Axelson, O; Carere, A; Forastiere, F; Iavarone, I; Lagorio, S; Tagesson, C, 1994
)
0.29
" The dose-response curves for three histamine concentrations (0."( Changes over 13 years in skin reactivity to histamine in cohorts of children aged 9-13 years.
Barreto, M; Ciofetta, G; Falasca, C; Martella, S; Pia Villa, M; Ronchetti, R, 2001
)
0.31
" A dosage increase of oxycodone from 20 to 40 mg bid was required in only one patient with a clavicle fracture."( Use of oxycodone in polytrauma patients: the "Gemelli" experience.
Barbaro, F; Buccelletti, F; Candelli, M; Carbone, L; De Marco, G; Fiore, V; Franceschi, F; Gabrielli, M; Gasbarrini, A; Gasbarrini, G; Gigante, G; Giupponi, B; Mancini, F; Marini, M; Ojetti, V; Pignataro, G; Roccarina, D; Santarelli, L; Silveri, NG; Ursella, S,
)
0.13
" Some AEs only occur when starting, increasing or discontinuing a treatment; in this case they are a function of dosage or drug levels at the target organs, or they may also be caused by drug interactions."( Adverse effects.
Rossini, PM, 2010
)
0.36
" Herein, we report one of the first applications of the QUEST-C method to quantify the exfiltration in a continuously operating sewer by dosing two chemical tracers, sodium bromide (NaBr) and lithium chloride (LiCl)."( Quantification of sewer leakage by a continuous tracer method.
Giulianelli, M; Prigiobbe, V, 2011
)
0.37
" Our own data and a review of the literature suggest that aged, hemodynamically frail patients, with several comorbidities and CKD, are at greater risk of MALA, despite MF dosage adjustment."( Metformin associated lactic acidosis (MALA): clinical profiling and management.
Coclite, D; Manzione, A; Maresca, B; Menè, P; Moioli, A; Napoletano, AM; Pirozzi, N; Punzo, G, 2016
)
0.43
"Intraoperative parathyroid hormone dosage allows real-time monitoring of the decrease in PTH levels during parathyroidectomy and verify procedure's efficacy."( Interpretation of intraoperative parathyroid hormone monitoring according to the Rome criterion in primary hyperparathyroidism.
Antonini, R; Calagna, S; Cipolla, C; Cocorullo, G; Contino, S; Corigliano, A; Graceffa, G; Mazzola, S; Melfa, G; Orlando, G; Proclamà, MP; Scerrino, G, 2022
)
0.95
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (6 Items)

ItemProcessFrequency
édulcoréescore-ingredient1
Boissonscore-ingredient1
Briochescore-ingredient1
Viennoiseriescore-ingredient1
Sweet snackscore-ingredient1
Snackscore-ingredient1

Roles (1)

RoleDescription
EC 2.7.1.91 (sphingosine kinase) inhibitorAn EC 2.7.1.* (phosphotransferases with an alcohol group as acceptor) inhibitor that interferes with the action of sphinganine kinase (EC 2.7.1.91).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
2-amino-2-(methoxymethyl)-4-(4-octylphenyl)butan-1-olAn aminoalcohol that is benzene substituted by a 3-amino-3-(hydroxymethyl)-4-methoxybutyl group at position 1 and an octyl group at position 4.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Sphingosine kinase 2Homo sapiens (human)IC50 (µMol)27.00000.35603.535210.0000AID1478831
Sphingosine kinase 2Homo sapiens (human)Ki18.60000.00368.805210.0000AID1077892; AID1151446; AID1304647; AID1705517; AID695248
Sphingosine kinase 1Homo sapiens (human)IC50 (µMol)50.00000.00081.30397.1000AID1478830
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (59)

Processvia Protein(s)Taxonomy
blood vessel developmentSphingosine kinase 2Homo sapiens (human)
positive regulation of cytokine production involved in immune responseSphingosine kinase 2Homo sapiens (human)
sphingosine-1-phosphate receptor signaling pathwaySphingosine kinase 2Homo sapiens (human)
sphinganine-1-phosphate biosynthetic processSphingosine kinase 2Homo sapiens (human)
sphingosine metabolic processSphingosine kinase 2Homo sapiens (human)
brain developmentSphingosine kinase 2Homo sapiens (human)
cell population proliferationSphingosine kinase 2Homo sapiens (human)
positive regulation of cell population proliferationSphingosine kinase 2Homo sapiens (human)
sphingolipid biosynthetic processSphingosine kinase 2Homo sapiens (human)
negative regulation of cell growthSphingosine kinase 2Homo sapiens (human)
positive regulation of interleukin-13 productionSphingosine kinase 2Homo sapiens (human)
positive regulation of interleukin-6 productionSphingosine kinase 2Homo sapiens (human)
positive regulation of tumor necrosis factor productionSphingosine kinase 2Homo sapiens (human)
positive regulation of mast cell activation involved in immune responseSphingosine kinase 2Homo sapiens (human)
positive regulation of apoptotic processSphingosine kinase 2Homo sapiens (human)
regulation of canonical NF-kappaB signal transductionSphingosine kinase 2Homo sapiens (human)
positive regulation of mast cell degranulationSphingosine kinase 2Homo sapiens (human)
transcription initiation-coupled chromatin remodelingSphingosine kinase 2Homo sapiens (human)
sphingosine biosynthetic processSphingosine kinase 2Homo sapiens (human)
positive regulation of protein kinase C signalingSphingosine kinase 2Homo sapiens (human)
positive regulation of calcium ion importSphingosine kinase 2Homo sapiens (human)
regulation of reactive oxygen species biosynthetic processSphingosine kinase 2Homo sapiens (human)
cellular response to phorbol 13-acetate 12-myristateSphingosine kinase 2Homo sapiens (human)
regulation of cytochrome-c oxidase activitySphingosine kinase 2Homo sapiens (human)
positive regulation of ceramide biosynthetic processSphingosine kinase 2Homo sapiens (human)
regulation of ATP biosynthetic processSphingosine kinase 2Homo sapiens (human)
phosphorylationSphingosine kinase 2Homo sapiens (human)
negative regulation of apoptotic processSphingosine kinase 1Homo sapiens (human)
positive regulation of fibroblast proliferationSphingosine kinase 1Homo sapiens (human)
blood vessel developmentSphingosine kinase 1Homo sapiens (human)
sphingosine-1-phosphate receptor signaling pathwaySphingosine kinase 1Homo sapiens (human)
protein acetylationSphingosine kinase 1Homo sapiens (human)
sphingosine metabolic processSphingosine kinase 1Homo sapiens (human)
inflammatory responseSphingosine kinase 1Homo sapiens (human)
brain developmentSphingosine kinase 1Homo sapiens (human)
cell population proliferationSphingosine kinase 1Homo sapiens (human)
positive regulation of peptidyl-threonine phosphorylationSphingosine kinase 1Homo sapiens (human)
regulation of tumor necrosis factor-mediated signaling pathwaySphingosine kinase 1Homo sapiens (human)
phosphorylationSphingosine kinase 1Homo sapiens (human)
calcium-mediated signalingSphingosine kinase 1Homo sapiens (human)
regulation of endocytosisSphingosine kinase 1Homo sapiens (human)
sphingolipid biosynthetic processSphingosine kinase 1Homo sapiens (human)
positive regulation of cell growthSphingosine kinase 1Homo sapiens (human)
positive regulation of cell migrationSphingosine kinase 1Homo sapiens (human)
positive regulation of protein ubiquitinationSphingosine kinase 1Homo sapiens (human)
regulation of interleukin-1 beta productionSphingosine kinase 1Homo sapiens (human)
positive regulation of interleukin-17 productionSphingosine kinase 1Homo sapiens (human)
response to tumor necrosis factorSphingosine kinase 1Homo sapiens (human)
intracellular signal transductionSphingosine kinase 1Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulusSphingosine kinase 1Homo sapiens (human)
negative regulation of apoptotic processSphingosine kinase 1Homo sapiens (human)
positive regulation of angiogenesisSphingosine kinase 1Homo sapiens (human)
positive regulation of mitotic nuclear divisionSphingosine kinase 1Homo sapiens (human)
positive regulation of mitotic cell cycleSphingosine kinase 1Homo sapiens (human)
positive regulation of smooth muscle contractionSphingosine kinase 1Homo sapiens (human)
sphingosine biosynthetic processSphingosine kinase 1Homo sapiens (human)
sphingoid catabolic processSphingosine kinase 1Homo sapiens (human)
regulation of phagocytosisSphingosine kinase 1Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activitySphingosine kinase 1Homo sapiens (human)
cellular response to hydrogen peroxideSphingosine kinase 1Homo sapiens (human)
DNA biosynthetic processSphingosine kinase 1Homo sapiens (human)
regulation of neuroinflammatory responseSphingosine kinase 1Homo sapiens (human)
negative regulation of ceramide biosynthetic processSphingosine kinase 1Homo sapiens (human)
positive regulation of p38MAPK cascadeSphingosine kinase 1Homo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionSphingosine kinase 1Homo sapiens (human)
regulation of microglial cell activationSphingosine kinase 1Homo sapiens (human)
regulation of endosomal vesicle fusionSphingosine kinase 1Homo sapiens (human)
cellular response to growth factor stimulusSphingosine kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (14)

Processvia Protein(s)Taxonomy
lipid kinase activitySphingosine kinase 2Homo sapiens (human)
protein bindingSphingosine kinase 2Homo sapiens (human)
ATP bindingSphingosine kinase 2Homo sapiens (human)
sphinganine kinase activitySphingosine kinase 2Homo sapiens (human)
D-erythro-sphingosine kinase activitySphingosine kinase 2Homo sapiens (human)
small GTPase bindingSphingosine kinase 2Homo sapiens (human)
sphingosine-1-phosphate receptor activitySphingosine kinase 2Homo sapiens (human)
histone bindingSphingosine kinase 2Homo sapiens (human)
magnesium ion bindingSphingosine kinase 1Homo sapiens (human)
lipid kinase activitySphingosine kinase 1Homo sapiens (human)
DNA bindingSphingosine kinase 1Homo sapiens (human)
protein bindingSphingosine kinase 1Homo sapiens (human)
calmodulin bindingSphingosine kinase 1Homo sapiens (human)
ATP bindingSphingosine kinase 1Homo sapiens (human)
lipid bindingSphingosine kinase 1Homo sapiens (human)
sphinganine kinase activitySphingosine kinase 1Homo sapiens (human)
acetyltransferase activitySphingosine kinase 1Homo sapiens (human)
D-erythro-sphingosine kinase activitySphingosine kinase 1Homo sapiens (human)
sphingosine-1-phosphate receptor activitySphingosine kinase 1Homo sapiens (human)
protein phosphatase 2A bindingSphingosine kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (16)

Processvia Protein(s)Taxonomy
nucleusSphingosine kinase 2Homo sapiens (human)
nucleoplasmSphingosine kinase 2Homo sapiens (human)
cytoplasmSphingosine kinase 2Homo sapiens (human)
mitochondrionSphingosine kinase 2Homo sapiens (human)
mitochondrial inner membraneSphingosine kinase 2Homo sapiens (human)
lysosomal membraneSphingosine kinase 2Homo sapiens (human)
endoplasmic reticulumSphingosine kinase 2Homo sapiens (human)
cytosolSphingosine kinase 2Homo sapiens (human)
membraneSphingosine kinase 2Homo sapiens (human)
nucleosomeSphingosine kinase 2Homo sapiens (human)
intracellular membrane-bounded organelleSphingosine kinase 2Homo sapiens (human)
membraneSphingosine kinase 2Homo sapiens (human)
cytoplasmSphingosine kinase 2Homo sapiens (human)
presynapseSphingosine kinase 1Homo sapiens (human)
nucleusSphingosine kinase 1Homo sapiens (human)
nucleoplasmSphingosine kinase 1Homo sapiens (human)
cytoplasmSphingosine kinase 1Homo sapiens (human)
cytosolSphingosine kinase 1Homo sapiens (human)
plasma membraneSphingosine kinase 1Homo sapiens (human)
clathrin-coated pitSphingosine kinase 1Homo sapiens (human)
endocytic vesicleSphingosine kinase 1Homo sapiens (human)
early endosome membraneSphingosine kinase 1Homo sapiens (human)
presynapseSphingosine kinase 1Homo sapiens (human)
intracellular membrane-bounded organelleSphingosine kinase 1Homo sapiens (human)
membraneSphingosine kinase 1Homo sapiens (human)
cytoplasmSphingosine kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID1478830Inhibition of human SphK1 using sphingosine as substrate after 15 to 20 mins in presence of [gamma-32P]ATP by Cerenkov counting method2017Bioorganic & medicinal chemistry, 06-15, Volume: 25, Issue:12
Identification of selective inhibitors of sphingosine kinases 1 and 2 through a structure-activity relationship study of 4-epi-jaspine B.
AID695248Inhibition of SphK2 using sphingosine as substrate and [32gammaP]ATP after 15 to 20 mins by Cerenkov counting analysis2012Bioorganic & medicinal chemistry letters, Nov-15, Volume: 22, Issue:22
Effect of alkyl chain length on sphingosine kinase 2 selectivity.
AID1705517Inhibition of recombinant SphK2 (unknown origin) using sphingosine as substrate incubated for 15 to 20 mins by [gamma32P]-ATP based assay2020European journal of medicinal chemistry, Nov-15, Volume: 206Structure-activity relationship studies and bioactivity evaluation of 1,2,3-triazole containing analogues as a selective sphingosine kinase-2 inhibitors.
AID1304647Inhibition of SphK2 (unknown origin)2016ACS medicinal chemistry letters, Mar-10, Volume: 7, Issue:3
Structure-Activity Relationship Studies and Molecular Modeling of Naphthalene-Based Sphingosine Kinase 2 Inhibitors.
AID1304648Inhibition of SphK1 (unknown origin)2016ACS medicinal chemistry letters, Mar-10, Volume: 7, Issue:3
Structure-Activity Relationship Studies and Molecular Modeling of Naphthalene-Based Sphingosine Kinase 2 Inhibitors.
AID1077892Inhibition of SK2 (unknown origin)2013MedChemComm, , Volume: 4, Issue:10
Novel sphingosine-containing analogues selectively inhibit sphingosine kinase (SK) isozymes, induce SK1 proteasomal degradation and reduce DNA synthesis in human pulmonary arterial smooth muscle cells.
AID1151446Inhibition of SphK2 (unknown origin)2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
Importance of sphingosine kinase (SphK) as a target in developing cancer therapeutics and recent developments in the synthesis of novel SphK inhibitors.
AID1478831Inhibition of human SphK2 using sphingosine as substrate after 15 to 20 mins in presence of [gamma-32P]ATP by Cerenkov counting method2017Bioorganic & medicinal chemistry, 06-15, Volume: 25, Issue:12
Identification of selective inhibitors of sphingosine kinases 1 and 2 through a structure-activity relationship study of 4-epi-jaspine B.
AID1345819Human sphingosine kinase 2 (Sphingosine kinase)2011Cellular signalling, Oct, Volume: 23, Issue:10
(R)-FTY720 methyl ether is a specific sphingosine kinase 2 inhibitor: Effect on sphingosine kinase 2 expression in HEK 293 cells and actin rearrangement and survival of MCF-7 breast cancer cells.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,564)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990853 (33.27)18.7374
1990's357 (13.92)18.2507
2000's399 (15.56)29.6817
2010's607 (23.67)24.3611
2020's348 (13.57)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 133.79

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index133.79 (24.57)
Research Supply Index8.10 (2.92)
Research Growth Index4.67 (4.65)
Search Engine Demand Index293.35 (26.88)
Search Engine Supply Index2.32 (0.95)

This Compound (133.79)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials87 (2.72%)5.53%
Reviews79 (2.47%)6.00%
Case Studies85 (2.66%)4.05%
Observational46 (1.44%)0.25%
Other2,897 (90.70%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]